Skip to Main Content

Paper Details

Statins for neuroprotection in spontaneous intracerebral hemorrhage.
Neurology
29
2019
ICH, Statin, Statins, brain injury, cerebral edema, dyslipidemia, hematoma, hemorrhagic stroke, inflammatory cell, intracerebral hemorrhage, mevalonate, oxygen, patients, perihematomal edema, spontaneous intracerebral hemorrhage, statin, statins
Animals, Cerebral Hemorrhage, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neuroprotective Agents
Author NameAffiliation
Ching-Jen ChenUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Dale DingUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Natasha IronsideUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Thomas J BuellUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Lori J ElderUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Amy WarrenUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Amy P AdamsUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Sarah J Ratcliffe (CM4AI)University of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Robert F JamesUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Neeraj S NavalUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Bradford B WorrallUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Karen C JohnstonUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
Andrew M SoutherlandUniversity of Virginia Health System, University of Louisville School of Medicine, KY Clinical Trials Office (L.J.E., University of Virginia School of Medicine Department of Pharmacology (A.P.A.), University of Virginia School of Medicine
  • 1 - 13

Datasets